Array
(
[actionDate] => 2020-09-29
[displayText] => Reported by the Committee on Energy and Commerce. H. Rept. 116-549.
[externalActionCode] => 5000
[description] => Introduced
[chamberOfAction] => House
)
Passed House
Array
(
[actionDate] => 2020-09-30
[displayText] => Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211).
[externalActionCode] => 8000
[description] => Passed House
[chamberOfAction] => House
)
TRANSPLANT Act of 2020 Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020
Official Titles
Official Titles - House of Representatives
Official Title as Introduced
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Actions Overview (3)
Date
Actions Overview
09/30/2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211).
09/29/2020
Reported by the Committee on Energy and Commerce. H. Rept. 116-549.
10/18/2019
Introduced in House
09/30/2020 Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211).
09/29/2020 Reported by the Committee on Energy and Commerce. H. Rept. 116-549.
10/18/2019 Introduced in House
All Actions (15)
Date
Chamber
All Actions
10/01/2020
Senate
Received in the Senate.
09/30/2020-4:28pm
House
Motion to reconsider laid on the table Agreed to without objection.
09/30/2020-4:28pm
House
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211). (text: CR 09/29/2020 H4996)
09/30/2020-3:45pm
House
Considered as unfinished business. (consideration: CR H5089-5090)
09/29/2020-2:15pm
House
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
09/29/2020-2:06pm
House
DEBATE - The House proceeded with forty minutes of debate on H.R. 4764.
09/29/2020-2:06pm
House
Considered under suspension of the rules. (consideration: CR H4996-4998)
09/29/2020-2:06pm
House
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
09/29/2020
House
Placed on the Union Calendar, Calendar No. 449.
09/29/2020
House
Reported by the Committee on Energy and Commerce. H. Rept. 116-549.
09/09/2020
House
Ordered to be Reported by Voice Vote. Action By: Committee on Energy and Commerce
09/09/2020
House
Committee Consideration and Mark-up Session Held. Action By: Committee on Energy and Commerce
10/21/2019
House
Referred to the Subcommittee on Health. Action By: Committee on Energy and Commerce
10/18/2019
House
Referred to the House Committee on Energy and Commerce.
10/18/2019
House
Introduced in House
10/01/2020 Received in the Senate.
09/30/2020 Motion to reconsider laid on the table Agreed to without objection.
09/30/2020 On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211). (text: CR 09/29/2020 H4996)
09/30/2020 Considered as unfinished business. (consideration: CR H5089-5090)
09/29/2020 At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
09/29/2020 DEBATE - The House proceeded with forty minutes of debate on H.R. 4764.
09/29/2020 Considered under suspension of the rules. (consideration: CR H4996-4998)
09/29/2020 Mr. Pallone moved to suspend the rules and pass the bill, as amended.
09/29/2020 Placed on the Union Calendar, Calendar No. 449.
09/29/2020 Reported by the Committee on Energy and Commerce. H. Rept. 116-549.
09/09/2020 Ordered to be Reported by Voice Vote.
09/09/2020 Committee Consideration and Mark-up Session Held.
10/21/2019 Referred to the Subcommittee on Health.
10/18/2019 Referred to the House Committee on Energy and Commerce.
Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020
This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.
Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.
In addition, the Government Accountability Office must examine various issues related to the national blood stem cell workforce.
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020
This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.
Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.
In addition, the Government Accountability Office must examine various issues related to the national blood stem cell workforce.
Shown Here: Reported to House (09/29/2020)
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019
This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments.
Shown Here: Introduced in House (10/18/2019)
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019
This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments.